FGF23 and PTH--double agents at the heart of CKD.

@article{Silver2012FGF23AP,
  title={FGF23 and PTH--double agents at the heart of CKD.},
  author={Justin Silver and Mariano Rodr{\'i}guez and Eduardo A Slatopolsky},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2012},
  volume={27 5},
  pages={
          1715-20
        }
}
  • J. Silver, Mariano Rodríguez, E. Slatopolsky
  • Published 1 May 2012
  • Medicine, Biology
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
The changes in mineral metabolism in chronic kidney disease (CKD) are well established as being major contributors to the morbidity and mortality of CKD patients, both early and established. The known factors involved were considered to be phosphate (P), calcium, parathyroid hormone (PTH), vitamin D and metabolic acidosis. A number of epidemiological studies have shown that high P associates with mortality; but more recently, the field has been invigorated by a new player, namely fibroblast… 

Figures from this paper

Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD)
  • O. Mosbah
  • Medicine, Biology
    Archives of Nephrology and Urology
  • 2019
TLDR
CKD-MBD was further expanded to include cardiovascular diseases (CVD), left ventricular hypertrophy, hypertension, immune dysfunction, inflammation and iron deficiency anemia, and thus its treatment is still a major challenge for the nephrologist that necessitates further pushing for the development of new agents with high specificity to the treatment of CKD induced MBD.
FGF-23 and secondary hyperparathyroidism in chronic kidney disease
TLDR
The mechanisms by which secondary hyperparathyroidism associated with CKD stimulates bone cells to overexpress FGF-23 levels are discussed, which includes local changes in the ratio of inorganic phosphate to pyrophosphate in bone.
FGF23: Is It Another Biomarker for Phosphate–Calcium Metabolism?
TLDR
The role of FGF23 in phosphate homeostasis, its relationship to mortality, fractures and chronic renal failure, and how the levels of this factor can be reduced are reviewed.
Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation.
  • G. Block, J. Ix, D. Wheeler
  • Medicine, Biology
    American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2013
TLDR
Interventions directed at lowering phosphate exposure and serum phosphate levels should be subject to rigorous clinical trials that use appropriate placebo comparators and focus on key clinical outcomes, such as cardiovascular events, progression of CKD, fractures, quality of life, and mortality.
Parathyroid Hormone as a Uremic Toxin
TLDR
Clinical practice guidelines recommend frequent measurement of PTH in order to determine trends and implement appropriate treatments, as well as having multiple effects on mineral metabolism associated with CKD.
Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease
TLDR
It is now apparent that calcitriol exerts an important effect on renal tubular reclamation of filtered 25(OH)-vitamin D, which may be vital for important pleiotropic actions in peripheral tissues through autocrine/paracrine mechanisms that impact the health of those local tissues.
Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
TLDR
The potential association of CV comorbidities with the older (parathyroid hormone, phosphate) and newer (FGF23, Klotho, sclerostin) CKD-MBD biomarkers is summarized.
The Influence of Dietary Interventions on Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)
TLDR
The results of studies suggest that progressive protein restriction is beneficial with the progression of renal insufficiency; however, other aspects of dietary management of CKD patients, including changes in sodium, phosphorus, and energy intake, as well as the source of protein and lipids should also be considered carefully.
Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?
...
...

References

SHOWING 1-10 OF 58 REFERENCES
High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.
  • G. Jean, J. Terrat, C. Chazot
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2009
TLDR
A high level of circulating FGF-23 in LHD patients, despite infrequent hyperphosphataemia is demonstrated, and the association of higher serum F GF-23 levels with mortality and VC, regardless of the serum phosphate levels, has been confirmed.
Latest findings in phosphate homeostasis.
TLDR
The role played by the FGF23-klotho axis in phosphate homeostasis and its involvement in the pathophysiology of phosphate disturbances in chronic kidney disease is described.
FGF-23 is elevated by chronic hyperphosphatemia.
TLDR
Serum FGF-23 levels are elevated in patients with hyperphosphatemia and chronic hypoparathyroidism, suggesting a feedback system in which serum F GF-23 responds to serum phosphorus and regulates it, as well as circumventing the confounding effect of serum PTH and calcium.
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.
TLDR
Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment, and a potential biomarker that can be used to guide strategies for the management of phosphorus balance in patients with chronic kidney disease is investigated.
FGF23 fails to inhibit uremic parathyroid glands.
TLDR
In hyperparathyroidism secondary to renal failure, the parathyroid cells resist the inhibitory effects of FGF23, perhaps as a result of the low expression of F GF23 receptor 1 and Klotho in this condition.
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23.
TLDR
In conclusion, FGF23 synergizes with PTH to increase renal phosphate excretion by reducing expression of the renal sodium-phosphate cotransporters Na Pi-IIa and NaPi-IIc in the proximal tubules.
Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure.
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.
TLDR
Elevated FGF-23 is an independent risk factor for end-stage renal disease in patients with relatively preserved kidney function and for mortality across the spectrum of chronic kidney disease.
Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo.
TLDR
The results show a direct and an indirect effect of PTH on FGF23 secretion, the former through changes in calcitriol concentrations, and Klotho expression in the kidney decreased after parathyroidectomy but was restored by hormone supplementation.
Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
TLDR
It is suggested that hyperplastic parathyroid glands, together with hyperphosphatemia, affect abnormal FGF-23 metabolism in patients with stage 5 CKD with advanced secondary hyperparathyroidism.
...
...